Would you like to receive updates
about ENHERTU?
What is HER2+ unresectable or metastatic breast cancer?
HER2 tells cells to grow
HER2 is a protein that tells cells to grow. In HER2+ breast cancer, the cancer cells have too much HER2, which leads to cancer growth.
Tumors form
These cancer cells grow and divide faster than healthy cells, causing tumors to form.
Cancer may spread
HER2+ breast cancer can spread to other parts of the body. This is known as HER2+ metastatic breast cancer (or HER2+ mBC). HER2+ unresectable breast cancer means it cannot be removed by surgery.
What is ENHERTU?
ENHERTU is a prescription medicine used to treat adults who have:
- Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
- for metastatic disease, or
- have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
It is not known if ENHERTU is safe and effective in children.
How is ENHERTU thought to work?
As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.
ENHERTU is made up
of an antibody with
the chemotherapy attached
of an antibody with
the chemotherapy attached
The antibody part of
ENHERTU targets and
attaches to HER2 on
the cancer cell
ENHERTU targets and
attaches to HER2 on
the cancer cell
ENHERTU enters
the cancer cell and the
chemotherapy is released
the cancer cell and the
chemotherapy is released
The chemotherapy part
of ENHERTU helps
destroy the cancer cell
as well as other
cells nearby
of ENHERTU helps
destroy the cancer cell
as well as other
cells nearby
Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells.
ENHERTU may not work for everyone.
How will I receive ENHERTU?
ENHERTU is taken alone, without the need for other medicines, to treat metastatic breast cancer
ENHERTU is given as an intravenous infusion (IV) once every 3 weeks
- ENHERTU has a treatment schedule that may be similar to other medicines you may have been prescribed before
The first infusion will take
about 90 minutes so the
healthcare provider can see
if there are any side effects or problems
about 90 minutes so the
healthcare provider can see
if there are any side effects or problems
Future infusions should
take about 30 minutes,
if your first infusion was well tolerated
take about 30 minutes,
if your first infusion was well tolerated
If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.
To help manage your side effects, your healthcare provider may:
Reduce your dose
Delay your dose
Stop ENHERTU
Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting.
HER2, human epidermal growth factor 2; mBC, metastatic breast cancer.
Not an actual patient.
